158 related articles for article (PubMed ID: 35176764)
1. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A; Garralda E; Altintas I; Gieseke F; Geva R; Ben-Ami E; Maurice-Dror C; Calvo E; LoRusso PM; Alonso G; Rodriguez-Ruiz ME; Schoedel KB; Blum JM; Sänger B; Salcedo TW; Burm SM; Stanganello E; Verzijl D; Vascotto F; Sette A; Quinkhardt J; Plantinga TS; Toker A; van den Brink EN; Fereshteh M; Diken M; Satijn D; Kreiter S; Breij ECW; Bajaj G; Lagkadinou E; Sasser K; Türeci Ö; Forssmann U; Ahmadi T; Şahin U; Jure-Kunkel M; Melero I
Cancer Discov; 2022 May; 12(5):1248-1265. PubMed ID: 35176764
[TBL] [Abstract][Full Text] [Related]
2. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
[TBL] [Abstract][Full Text] [Related]
3. Striking the Balance with a PD-L1×4-1BB Bispecific Antibody.
Ha J; Grippin AJ; Kim BYS; Jiang W
Cancer Res; 2024 May; 84(10):1546-1547. PubMed ID: 38745496
[TBL] [Abstract][Full Text] [Related]
4. Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.
Odegard JM; Othman AA; Lin KW; Wang AY; Nazareno J; Yoon OK; Ling J; Lad L; Dunbar PR; Thai D; Ang E; Waldron N; Deva S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604815
[TBL] [Abstract][Full Text] [Related]
5. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.
Rubio-Pérez L; Frago S; Compte M; Navarro R; Harwood SL; Lázaro-Gorines R; Gómez-Rosel M; Hangiu O; Silva-Pilipich N; Vanrell L; Smerdou C; Álvarez-Vallina L
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38804302
[TBL] [Abstract][Full Text] [Related]
7. Development of Plant-Derived Bispecific Monoclonal Antibody Targeting PD-L1 and CTLA-4 against Mouse Colorectal Cancer.
Bulaon CJI; Khorattanakulchai N; Rattanapisit K; Sun H; Pisuttinusart N; Phoolcharoen W
Planta Med; 2024 Apr; 90(4):305-315. PubMed ID: 38373705
[TBL] [Abstract][Full Text] [Related]
8. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
9. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
Geuijen C; Tacken P; Wang LC; Klooster R; van Loo PF; Zhou J; Mondal A; Liu YB; Kramer A; Condamine T; Volgina A; Hendriks LJA; van der Maaden H; Rovers E; Engels S; Fransen F; den Blanken-Smit R; Zondag-van der Zande V; Basmeleh A; Bartelink W; Kulkarni A; Marissen W; Huang CY; Hall L; Harvey S; Kim S; Martinez M; O'Brien S; Moon E; Albelda S; Kanellopoulou C; Stewart S; Nastri H; Bakker ABH; Scherle P; Logtenberg T; Hollis G; de Kruif J; Huber R; Mayes PA; Throsby M
Nat Commun; 2021 Jul; 12(1):4445. PubMed ID: 34290245
[TBL] [Abstract][Full Text] [Related]
10. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL
Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798
[No Abstract] [Full Text] [Related]
12. XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models.
Wang B; Liu Y; Yuan R; Dou X; Qian N; Pan X; Xu G; Xu Q; Dong B; Yang C; Li H; Wang J; Bai G; Liu L; Gao X
Cancer Immunol Immunother; 2023 Dec; 72(12):4015-4030. PubMed ID: 37863852
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.
Cheng L; Chen L; Shi Y; Gu W; Ding W; Zheng X; Liu Y; Jiang J; Zheng Z
Mol Cancer; 2024 Apr; 23(1):77. PubMed ID: 38627681
[TBL] [Abstract][Full Text] [Related]
14. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
[TBL] [Abstract][Full Text] [Related]
15. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional bispecific nanovesicles targeting SLAMF7 trigger potent antitumor immunity.
Zhu M; Wu Y; Zhu T; Chen J; Chen Z; Ding H; Tan S; He J; Zeng Q; Huang X
Cancer Immunol Res; 2024 May; ():. PubMed ID: 38819238
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.
Navarro R; Frago S; Hangiu O; Erce-Llamazares A; Lázaro-Gorines R; Morcillo MA; Rodriguez-Peralto JL; Sanz L; Compte M; Alvarez-Vallina L
Toxicol Appl Pharmacol; 2024 Jun; 487():116961. PubMed ID: 38740095
[TBL] [Abstract][Full Text] [Related]
18. Development of bispecific T cell engagers: harnessing quantitative systems pharmacology.
Qi T; Liao X; Cao Y
Trends Pharmacol Sci; 2023 Dec; 44(12):880-890. PubMed ID: 37852906
[TBL] [Abstract][Full Text] [Related]
19. Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed
Noguchi Y; Yan M; Tachi T; Yoshimura T
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649281
[No Abstract] [Full Text] [Related]
20. Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse.
Meng Q; Hao Y; Yang M; Du Y; Wang S
J Pharm Biomed Anal; 2024 Aug; 245():116138. PubMed ID: 38636191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
